Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.

Delin Kong; Tingting Yang; Jia Geng; Ruirui Jing; Qiqi Zhang; Guoqing Wei; He Huang; Yongxian HU

Return

Secondary donor-derived CD19 CAR-T therapy is safe and efficacious in acute lymphoblastic leukemia with extramedullary relapse after first autologous CAR-T therapy.

Author: Delin KONG ¹ ; Tingting YANG ¹ ; Jia GENG ² ; Ruirui JING ¹ ; Qiqi ZHANG ¹ ; Guoqing WEI ¹ ; He HUANG ¹ ; Yongxian HU ³
Author Information

1. Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
2. Department of Radiology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
3. Bone Marrow Transplantation Center, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China. 1313016@zju.edu.cn.
Publication Type:Journal Article
MeSH: Adult; Antigens, CD19; Hematopoietic Stem Cell Transplantation; Humans; Immunotherapy, Adoptive/adverse effects*; Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy*; Receptors, Chimeric Antigen; Recurrence
From: Journal of Zhejiang University. Science. B 2022;23(10):876-880
CountryChina
Language:English
Abstract: Despite the advancement of treatments, adults with relapsed/refractory (R/R) B-lineage acute lymphoblastic leukemia (B-ALL) have poor prognosis, with an expected five-year overall survival (OS) rate of 10%‒20% (Nguyen et al., 2008; Oriol et al., 2010). Extramedullary relapse of B-ALL is regarded as a high-risk factor generally associated with poor survival, occurring in about 15% to 20% of all relapsed patients (Ding et al., 2017; Sun et al., 2018). The central nervous system (CNS) and the testes are the most common sites of extramedullary relapse of B-ALL. In addition, extramedullary leukemia can appear in the skin, eyes, breasts, bones, muscles, and abdominal organs. The prognosis of relapsed extramedullary B-ALL after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is extremely poor (Spyridonidis et al., 2012; Dahlberg et al., 2019). Conventional chemotherapy or radiation is often ineffective in such patients. At present, there are no optimal treatment strategies for treating extramedullary leukemia after allo-HSCT.